February 7, 2025Open Access

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

Key Points

Key points are not available for this paper at this time.

Abstract

Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response. (Funded by F. Hoffmann-La Roche; REGENCY ClinicalTrials.gov number, NCT04221477.).

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Furie et al. (Fri,) studied this question.

synapsesocial.com/papers/69d7ca08319e71454dbeda46 https://doi.org/https://doi.org/10.1056/nejmoa2410965

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the <scp>NOBILITY</scp> Trial2023 · 46 citations
2POS0529 OBINUTUZUMAB BENEFITS PATIENTS WITH ACTIVE LUPUS NEPHRITIS IRRESPECTIVE OF BASELINE PROTEINURIA SEVERITY: A POST HOC ANALYSIS OF THE PHASE II NOBILITY TRIAL2024 · 1 citations
3A New Equation to Estimate Glomerular Filtration Rate2009 · 25,724 citations
4Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency2019 · 562 citations
5Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients2021 · 90 citations

AI에게 질문

Bookmark

View Full Paper